<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671645</url>
  </required_header>
  <id_info>
    <org_study_id>ABCSG R04/TAKO 08</org_study_id>
    <nct_id>NCT00671645</nct_id>
  </id_info>
  <brief_title>Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy</brief_title>
  <official_title>Preoperative Combined RadioChemo-MolecularTargetTherapy of the Locally Advanced Rectum Carcinoma (cT3NxM0) - a Phase II Pilot Study With Preoperative Application of Capecitabine, Bevacizumab and Radiotherapy (RTx)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Breast &amp; Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Austrian Breast &amp; Colorectal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  feasibility and tolerance of preoperative therapy with Bevacizumab in combination with&#xD;
           Capecitabine and radiotherapy for patients with locally advanced, locally operable&#xD;
           rectal carcinoma&#xD;
&#xD;
        -  collection of response rate (T- and M-downstaging, pathological complete remission)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combined RadioChemotherapy:&#xD;
&#xD;
      Therapy start: within 28 days after bioptical diagnosis&#xD;
&#xD;
      Radiotherapy: 5 x 5 days 1.8 Gy radiotherapy; cummulative dose 45 Gy&#xD;
&#xD;
      Chemotherapy: Capecitabin 825mg/m² bid, on each radiation day during the first 4 weeks RCTx&#xD;
&#xD;
      Molecular Targeted Therapy: Bevacizumab 5 mg/kg body weight; day 1, 15, 29 Operation due to&#xD;
      TME adherence to a break of min. 42 to max. 56 days after the last application of bevacizumab&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    reaching of step 1 (recruitment of 8 patients) per protocol -&gt; risk assessment -&gt; termination&#xD;
    because of occurance of toxicity Grade 3 and 4&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">February 27, 2009</completion_date>
  <primary_completion_date type="Actual">February 27, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>feasibility and tolerance of preoperative therapy with Bevacizumab in combination with Capecitabine and radiotherapy for patients with locally advanced, locally operable rectal carcinoma</measure>
    <time_frame>descriptive evaluation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>collection of response rate (T- and M-downstaging, pathological complete remission)</measure>
    <time_frame>descriptive evaluation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine, bevacizumab</intervention_name>
    <description>Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xeloda</other_name>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age: 18 - 80&#xD;
&#xD;
          -  bioptical confirmed adenocarcinoma of the rectum in T3NxM0 status. The tumor has to be&#xD;
             basically surgically complete resectable (-&gt;R0).&#xD;
&#xD;
          -  no former chemotherapy, radiotherapy of pelvis or abdomen and/or tumor resection of&#xD;
             rectum carcinoma&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  adequate bone marrow reserve (granulocytes &gt;= 3.000/µl, absolute neutrophil &gt;= 0 1,5 x&#xD;
             10 9/l thrombocytes: &gt;= 100.000/µl, haemoglobin &gt;= 10g/dl)&#xD;
&#xD;
          -  adequate hepatic function (Bilirubin: &lt;= 1.5 x ULN, GOT und GPT &lt;= 2.5 x ULN)&#xD;
&#xD;
          -  adequate renal function (creatinin: &lt;= 1.25 mg/dl, creatinin-clearance: &gt; 50 ml/min&#xD;
             (Cockcroft and Gault formula)), proteinuria: dipstick &lt; 2+. In case of dipstick &gt; 2+&#xD;
             protein has to be measured in 24h urine and does not exceed more than 1g/24h)&#xD;
&#xD;
          -  ability of intake of pills&#xD;
&#xD;
          -  women of childbearing potential: exclusion of pregnancy (negative urin or serum&#xD;
             pregnancy test)&#xD;
&#xD;
          -  willingness of women of childbearing potential and accordingly of potent men to use&#xD;
             approved contraceptives (e.g. birth-control pill, loop, condom) during and at least 3&#xD;
             month after conclusion of the study&#xD;
&#xD;
          -  life expectancy of at least 3 month&#xD;
&#xD;
          -  INR and aPTT &lt; 1.5 ULN&#xD;
&#xD;
          -  signed Informed Consent before recruitment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  failure of one inclusion criteria&#xD;
&#xD;
          -  former radiotherapy of pelvis or abdomen&#xD;
&#xD;
          -  former chemotherapy&#xD;
&#xD;
          -  any other kind of malign tumor in the last 5 years&#xD;
&#xD;
          -  any other kind of tumour in the last 5 years with exception of basal cell carcinoma of&#xD;
             skin and cervix carcinoma in situ&#xD;
&#xD;
          -  general contraindication or known hypersensitivity against Bevacizumab and/or&#xD;
             Capecitabine&#xD;
&#xD;
          -  non malign disease, if there is a contraindication with radiotherapy, or chemotherapy&#xD;
             with Bevacizumab and Capecitabine, or a resection of rectum: uncontrolled hypertension&#xD;
             (systolic &gt; 150 mmHG and/or diastolic &gt;100 mmHG) or clinical significant (e.g. active)&#xD;
             cardiovascular disease: CVA (cardiovascular accident)/ cerebral apoplexy (&lt; 6 months&#xD;
             before recruitment), myocardial infarct (&lt; 6 months before recruitment), instable&#xD;
             angina pectoris, CHF with NYHA status II or higher, or treated serious arrhythmia,&#xD;
             hepatic disease, significant neurologic or psychiatric disorders&#xD;
&#xD;
          -  florid, serious infections at the time of recruitment&#xD;
&#xD;
          -  peripheral neuropathy (NCI CTC &gt;= Grade 1)&#xD;
&#xD;
          -  legally limited contractual capability or evidence of neurological or psychiatric&#xD;
             disease, if it will constrict the patients compliance in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          -  evidence of lacking cooperation of the patient&#xD;
&#xD;
          -  major intervention within 28 days before recruitment, open wounds&#xD;
&#xD;
          -  serious injuries, unhealed wounds or fractures&#xD;
&#xD;
          -  patients with spinal compressions or metastases in central nervous system&#xD;
&#xD;
          -  evidence of bleeding diathesis or coagulation dysfunction&#xD;
&#xD;
          -  actual intake of anticoagulant or thrombolytic agents, Aspirin &gt; 325 mg/d or within 10&#xD;
             days before study start)&#xD;
&#xD;
          -  actual or recent (within 10 days before recruitment) therapeutic therapy with&#xD;
             fully-dosed anticoagulants. A prophylactic treatment is permitted.&#xD;
&#xD;
          -  previous thromboembolic or hemorrhagic events within the last 6 months before&#xD;
             recruitment&#xD;
&#xD;
          -  previous abdominal fistulas, GI perforation or intra-abdominal abscess within the last&#xD;
             6 months&#xD;
&#xD;
          -  treatment with other study medication within 28 days before recruitment&#xD;
&#xD;
          -  patients with malabsorption syndrome or difficulties swallowing&#xD;
&#xD;
          -  pregnant or breast feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietmar Oefner, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander de Vries, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austrian Breast &amp; Colorectal Cancer Study Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Eisterer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ABCSG, TAKO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital BHB St. Veit/Glan, Surgery</name>
      <address>
        <city>St. Veit/Glan</city>
        <state>Carinthia</state>
        <zip>9300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Graz, Oncology</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Leoben, Surgery</name>
      <address>
        <city>Leoben</city>
        <state>Styria</state>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck, Internal Medicine</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital BHS Linz, Radiooncology</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen, Coop. Group</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Feldkirch, Radiotherapy</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Hospital Salzburg-Paracelsius Medical University - Oncology</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital BHB Vienna, Surgery</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Radiotherapy</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.abcsg.at</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 30, 2008</study_first_submitted>
  <study_first_submitted_qc>April 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pilot study</keyword>
  <keyword>rectal</keyword>
  <keyword>carcinoma</keyword>
  <keyword>phase II</keyword>
  <keyword>preoperative</keyword>
  <keyword>RadioChemo</keyword>
  <keyword>molecular</keyword>
  <keyword>target</keyword>
  <keyword>therapy</keyword>
  <keyword>T3</keyword>
  <keyword>ABCSG</keyword>
  <keyword>TAKO</keyword>
  <keyword>R04</keyword>
  <keyword>08</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

